On October 31, 2025, the investigator meeting of "multicenter, randomized, double-blind, positive drug parallel controlled, non inferiority clinical trial to evaluate the efficacy and safety of beclomethasone formoterol inhalation aerosol in the treatment of adult bronchial asthma" initiated by Leecan pharmaceutical was successfully held in Nanjing. The meeting was led by Professor linjiangtao of the China Japan Friendship Hospital, the main researcher, and well-known experts from 28 participating centers across the country, together with representatives of Leecan Pharmaceutical Research Institute and cooperative cro, to conduct in-depth discussions on key topics such as trial scheme design, project plan, quality management and potential risks.

    The founder of Leecan pharmaceutical attended the meeting and participated in the whole discussion. In his opening speech, he extended a warm welcome and heartfelt thanks to Professor linjiangtao and the participating experts, and introduced the development history and product layout of Leecan pharmaceutical. He hopes to rely on the profound knowledge and clinical experience of all experts to jointly solve the key difficulties in the clinical research and ensure the successful achievement of the scientific objectives of the trial. He also shared the clinical research series monographs edited by him with the participating experts, hoping to provide systematic support from theoretical construction to practical application for colleagues in the industry.

    In the discussion session, the founder of Leecan pharmaceutical and Professor linjiangtao and other experts conducted in-depth discussions around the core issues such as research objectives, applicable populations and treatment plans, and fully demonstrated the technical details and implementation steps in the test plan, ensuring that all parties involved in the study accurately understand the test plan and carry out relevant work in strict accordance with the plan and GCP specifications.

    At the closing session, the founder of Leecan pharmaceutical expressed his heartfelt thanks to the experts for their valuable opinions. As the R & D and production enterprise of this product and the sponsor of clinical trials, we will fully digest and absorb the results of this meeting, provide the key basis for the application for listing of this product with scientific, rigorous and reliable clinical research results, and provide patients with safer, reliable and effective new treatment options as soon as possible.

    The meeting gathered the wisdom and experience of experts from all sides and laid a solid foundation for the follow-up promotion of the project. Based on this meeting, all parties involved in the study will further gather consensus and work together to actively promote the phase III clinical trial of beclomethasone formoterol inhalation aerosol, promote the early implementation of innovative achievements, and benefit the majority of patients.